Monk Fruit

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: weight heart inflammation

Research Overview

Overall, monk fruit (Siraitia grosvenorii; Luo Han Guo) research is concentrated in three main areas: (1) characterization of its sweet constituents (mogrosides, especially mogroside V) and the plant’s phytochemistry; (2) production biology, including genomics, transcriptomics, and synthetic biology approaches to elucidate and potentially engineer the mogroside biosynthetic pathway; and (3) food science and sensory evaluation of monk fruit extract as a high-intensity, non-sugar sweetener. Reviews also situate monk fruit within the broader nutraceutical marketplace and traditional Chinese food/medicine context, while emerging bibliometric work indicates a growing and increasingly mapped literature base.

The strongest evidence supported by these studies is for monk fruit’s role as a potent non-sugar sweetener and for a well-defined biosynthetic basis of mogroside V production. Genomic and functional-expression studies have identified key enzyme families involved in mogroside V biosynthesis, providing robust mechanistic support for how sweetness compounds are produced and enabling rational strategies for improved production. In applied sensory research, controlled temporal profiling indicates monk fruit extract can differ substantially from sucrose in sweetness dynamics and is often associated with lingering bitterness/metallic/chemical notes at equi-sweet levels, which is important evidence for formulation constraints and consumer acceptance considerations in sugar-reduction applications.

Areas needing more research include translation of proposed health benefits from preclinical and mechanistic studies to humans, including well-controlled clinical trials assessing efficacy, dosing, and safety for specific indications. For example, anti-inflammatory and antioxidant effects of mogroside V have been demonstrated in an animal model of ulcerative colitis with mechanistic links to endoplasmic reticulum stress–apoptosis pathways, but human relevance and clinical effectiveness remain uncertain based on the studies reviewed here. Additional needs include improved sensory/formulation strategies to mitigate off-tastes (e.g., blending with other sweeteners, matrix effects in foods such as dairy), standardized characterization of monk fruit preparations (extract composition, mogroside profiles), and continued work on scalable, sustainable production (including synthetic biology) with attention to product consistency and regulatory-quality specifications.

1. What conditions has Monk Fruit been studied for?

  • Ulcerative colitis (UC): Mogroside V (an active compound in monk fruit) was tested in a mouse model of DSS-induced colitis, with mechanistic focus on endoplasmic reticulum stress (ERS) and ERS-induced apoptosis pathways.

  • Metabolic conditions (preclinical focus): Reviews and a bibliometric analysis report recurring research themes around anti-hyperglycemic/anti-diabetic and anti-hyperlipidemic effects, largely in animal models, with limited clinical trial evidence.

  • Food reformulation to reduce added sugar intake (diet-related health risk mitigation): Multiple studies discuss monk fruit extract/mogrosides as non-sugar, non-nutritive high-intensity sweeteners used to replace sucrose in foods and beverages (e.g., dairy products), motivated by public health concerns about excess added sugar.

  • Product/food science outcomes (not diseases, but relevant to use): Studies examined sensory properties (taste profile vs sucrose and other sweeteners) and effects in dairy matrices (e.g., camel milk drinking yogurt; chocolate milk formulation work described but abstract is truncated).

2. Does it work in treating those conditions? Summarize the evidence.

  • Ulcerative colitis (animal evidence only in provided studies): In DSS-induced UC in mice, mogroside V improved multiple disease indicators (lower disease activity index, longer colon length, improved histology, lower pro-inflammatory cytokines, and decreased intestinal permeability). Mechanistically, it reduced ERS pathway markers (BIP, PERK, eIF2α, ATF4, CHOP) and ERS-associated apoptosis markers (including Caspase-12, Bcl-2/Bax changes). Importantly, adding tunicamycin (an ERS activator) weakened mogroside V’s benefit, supporting (but not proving) an ERS-mediated mechanism.

    Limitations: This is a mouse model; the studies reviewed here do not include human UC trials, so clinical effectiveness is unknown.

  • Diabetes / hyperglycemia / hyperlipidemia (mostly preclinical): A bibliometric analysis and reviews indicate these are common reported “health effects,” but also explicitly note that most evidence is from animal models with limited clinical trials, and that future studies should focus on testing in humans. Based on the studies reviewed here, effectiveness in humans cannot be concluded.

  • Reducing sugar intake (functional effectiveness as a sweetener): Monk fruit extract/mogrosides are described as high-intensity sweeteners (mogroside V reported as ~250× sweeter than sucrose in one abstract; another notes ~100–250×). This supports effectiveness for sweetness replacement, but it is not direct evidence of treating a medical condition.

3. What health benefits does it have?

  • Potential anti-inflammatory and antioxidant activity (preclinical/mechanistic): Reviews describe monk fruit (Siraitia grosvenorii) bioactives as having antioxidant and anti-inflammatory activities, and the UC mouse study reports reduced inflammatory cytokines and ERS/apoptosis signaling with mogroside V.

  • Potential metabolic benefits (mostly animal evidence): The bibliometric analysis highlights recurring themes of anti-hyperglycemic/anti-diabetic and anti-hyperlipidemic effects, but emphasizes limited clinical trial evidence.

  • Dietary/public health benefit via sugar reduction: Multiple studies frame monk fruit sweetener as a tool to replace sucrose in foods and beverages to help reduce added sugar and calorie intake, aligning with public health goals (e.g., WHO recommendations to cut sugar in processed foods). This is an indirect health benefit (through reduced sugar exposure), not a proven therapeutic effect of monk fruit itself.

  • Food formulation compatibility (supporting practical use): In camel milk drinking yogurt, adding monk fruit sweetener did not impair growth of key yogurt cultures/probiotics measured (S. thermophilus, L. bulgaricus, L. acidophilus), suggesting it can be used without obvious disruption of these microbiological counts in that product context.

4. Does it have any downsides or side effects?

  • Sensory downsides (taste/aftertaste): In a temporal sensory profiling study comparing 15 sweeteners at equi-sweet intensity, luo han guo (monk fruit extract/mogroside) showed prominent and long-lasting undesirable side tastes (notably bitter, metallic, and chemical attributes) and lower sweetness citations compared with sucrose. This can limit acceptability and may require blending with other sweeteners in product formulation.

  • Formulation effects in foods: In camel milk drinking yogurt, monk fruit sweetener significantly affected pH, viscosity, and color parameters. These are not necessarily “side effects” in humans, but they are practical downsides for product development and consumer acceptance.

  • Safety signals in the studies reviewed here: The bibliometric abstract notes monk fruit extracts are generally recognized as safe (GRAS) by the US FDA. The studies reviewed here do not describe specific adverse events in humans, dose-related toxicity, or common side effects; therefore, no evidence-based side-effect profile can be concluded from these studies alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic findings (i.e., no data linking monk fruit extract or mogrosides to specific genetic variants affecting efficacy, safety, metabolism, or response). Therefore:

  • No evidence from these studies that monk fruit is specifically beneficial or harmful for any known genetic variations.

  • Key limitation: Without human clinical studies that stratify outcomes by genotype (or mechanistic studies of mogroside metabolism/transport with genetic variability), pharmacogenomic conclusions cannot be made.

References

  1. Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals.
    Elizabeth M Williamson, Xinmin Liu, Angelo A Izzo (2020) - British journal of pharmacology
  2. Siraitia grosvenoriiAs a Homologue of Food and Medicine: A Review of Biological Activity, Mechanisms of Action, Synthetic Biology, and Applications in Future Food
    Yuxi Guo, Xuefeng Chen, Pin Gong, Hui Long, Jiating Wang (2024)
  3. The biosynthetic pathway of the nonsugar, high-intensity sweetener mogroside V from Siraitia grosvenorii.
    Maxim Itkin, Rachel Davidovich-Rikanati, Shahar Cohen, Vitaly Portnoy, Adi Doron-Faigenboim, Elad Oren, Shiri Freilich, Galil Tzuri, Nadine Baranes, Shmuel Shen, Marina Petreikov, Rotem Sertchook, Shifra Ben-Dor, Hugo Gottlieb, Alvaro Hernandez, David R Nelson, Harry S Paris, Yaakov Tadmor, Yosef Burger, Efraim Lewinsohn, Nurit Katzir, Arthur Schaffer (2016) - Proceedings of the National Academy of Sciences of the United States of America
  4. Temporal sweetness and side tastes profiles of 16 sweeteners using temporal check-all-that-apply (TCATA).
    Vicki Wei Kee Tan, May Sui Mei Wee, Oliver Tomic, Ciaran G Forde (2019) - Food research international (Ottawa, Ont.)
  5. Mogroside V reduced the excessive endoplasmic reticulum stress and mitigated the Ulcerative colitis induced by dextran sulfate sodium in mice.
    Yue-Rong Tan, Si-Yang Shen, Xin-Yi Li, Peng-Fei Yi, Ben-Dong Fu, Lu-Yuan Peng (2024) - Journal of translational medicine
  6. Sugar Reduction in Dairy Food: An Overview with Flavoured Milk as an Example.
    Dipendra Kumar Mahato, Russell Keast, Djin Gie Liem, Catherine Georgina Russell, Sara Cicerale, Shirani Gamlath (2020) - Foods (Basel, Switzerland)
  7. Bibliometric analysis on the literature of monk fruit extract and mogrosides as sweeteners.
    Andy Wai Kan Yeung (2023) - Frontiers in nutrition
  8. Physicochemical and microbiological characteristics of camel milk yogurt as influenced by monk fruit sweetener.
    Alina Buchilina, Kayanush Aryana (2021) - Journal of dairy science
  9. Parents' and children's acceptance of skim chocolate milks sweetened by monk fruit and stevia leaf extracts.
    X E Li, K Lopetcharat, M A Drake (2015) - Journal of food science
  10. Prediction of the sweetening effect of Siraitia grosvenorii (luo han guo) fruits by two-dimensional quantitative NMR.
    Serhat S Çiçek, Tiffany Esposito, Ulrich Girreser (2021) - Food chemistry
  11. Abundance and diversity of fungal endophytes isolated from monk fruit (
    Li Ma, Janice F Elmhirst, Rojin Darvish, Lisa A Wegener, Deborah Henderson (2024) - Plant-environment interactions (Hoboken, N.J.)
  12. Effects of non-nutritive (artificial vs natural) sweeteners on 24-h glucose profiles.
    S L Tey, N B Salleh, C J Henry, C G Forde (2017) - European journal of clinical nutrition
  13. The effects of commercially available sweeteners (sucrose and sucrose replacers) on wheat starch gelatinization and pasting, and cookie baking.
    Travest J Woodbury, Andres L Lust, Lisa J Mauer (2021) - Journal of food science
  14. Siraitia grosvenorii Residual Extract Attenuates Atopic Dermatitis by Regulating Immune Dysfunction and Skin Barrier Abnormality.
    Yoon-Young Sung, Heung-Joo Yuk, Won-Kyung Yang, Seung-Hyung Kim, Dong-Seon Kim (2020) - Nutrients
  15. Effect of synbiotic yogurt fortified with monk fruit extract on hepatic lipid biomarkers and metabolism in rats with type 2 diabetes.
    Qingfeng Ban, Xiaomeng Sun, Yunqing Jiang, Jianjun Cheng, Mingruo Guo (2022) - Journal of dairy science
  16. Role of sweeteners on temporality and bar hardening of protein bars.
    H R M Keefer, S Nishku, P D Gerard, M A Drake (2020) - Journal of dairy science
  17. Physiochemical and Microbiological Stability of Azathioprine Suspensions in PCCA Base, SuspendIt.
    Yahoda V Pramar, Tarun K Mandal, Levon A Bostanian, Cyndy Kader, Tommy C Morris, Richard A Graves (2023) - International journal of pharmaceutical compounding
  18. Recent evidence for the effects of nonnutritive sweeteners on glycaemic control.
    Samar Y Ahmad, Meghan B Azad, James Friel, Dylan MacKay (2019) - Current opinion in clinical nutrition and metabolic care
  19. Plant Metabolic Engineering by Multigene Stacking: Synthesis of Diverse Mogrosides.
    Jingjing Liao, Tingyao Liu, Lei Xie, Changming Mo, Xiyang Huang, Shengrong Cui, Xunli Jia, Fusheng Lan, Zuliang Luo, Xiaojun Ma (2022) - International journal of molecular sciences
  20. In search for an alternative to sugar to reduce obesity
    Arshag D Mooradian (2019)


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!